Insilico Medicine (03696) has announced that it completed first-in-human dosing of ISM9528 just four months after the candidate was nominated as a preclinical candidate (PCC). ISM9528 is a potential first-in-class non-opioid pain treatment discovered in Abu Dhabi.
The exploratory trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ISM9528 in healthy adult volunteers. As the study progresses, Insilico Medicine may submit additional documents to the relevant regulatory authorities and, subject to regulatory approval, expand this exploratory trial.
ISM9528 was nominated as a PCC by Insilico Medicine's Abu Dhabi team in July 2026, becoming the company's 31st PCC since 2021 and the second PCC generated from its UAE research and development efforts. In preclinical studies, ISM9528, as a potential oral therapy, demonstrated efficacy superior to standard treatments in validated models of acute postoperative pain and neuropathic pain. In addition, comprehensive in vitro and in vivo safety screening across multiple test panels and animal models indicated a favorable safety profile, while rapid systemic absorption and excellent blood-brain barrier penetration support favorable DMPK characteristics.
Comments